利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

165 records (took 0.02 seconds)

    USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY
    6.
    发明公开
    USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY 审中-公开

    公开(公告)号：US20230225986A1

    公开(公告)日：2023-07-20

    申请号：US18002437

    申请日：2021-06-16

    Applicant: GW Research Limited

    Inventor： Jie LI ,  Kevin CRAIG ,  Daniel CHECKETTS ,  David CRITCHLEY

    IPC: A61K31/05 ,  A61K31/522

    CPC classification number: A61K31/05 ,  A61K31/522

    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking caffeine. Where the CBD is used in combination with caffeine, caution should be taken. For example, the dose of either the CBD and/or caffeine may be required to be reduced. Moreover, the patient may need to be monitored for side effects of said drug-drug interaction. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

    Use of cannabinoids in the treatment of Angelman syndrome
    8.
    发明授权
    Use of cannabinoids in the treatment of Angelman syndrome 有权

    公开(公告)号：US11679087B2

    公开(公告)日：2023-06-20

    申请号：US16467639

    申请日：2017-12-13

    Applicant: GW RESEARCH LIMITED

    Inventor： Geoffrey Guy ,  Stephen Wright ,  James Brodie ,  Marie Woolley-Roberts ,  Livio Luongo

    IPC: A61K31/05 ,  A61P25/20 ,  A61K36/185 ,  A61K45/06

    CPC classification number: A61K31/05 ,  A61K36/185 ,  A61K45/06 ,  A61P25/20

    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Angelman syndrome (AS). CBD has been shown to be particularly effective in improving anxiety in rodent models of AS. The CBD is preferably substantially pure. It may take the form of a highly purified extract of Cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBD is synthetically produced. Alternatively, the CBD may be used as a botanical drug substance (BDS) from a Cannabis plant in which CBD is the predominant cannabinoid. The CBD may also be present in combination with other cannabinoids and non-cannabinoid components such as terpenes. In use the CBD may be used concomitantly with one or more other medicaments. Alternatively, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more medicaments or the combination may be provided in a single dosage form. Where the CBD is formulated for administration separately, sequentially or simultaneously it may be provided as a kit or together with instructions to administer the one or more components in the manner indicated. It may also be used as the sole medication, i.e. as a monotherapy.

Patent Agency Ranking